Abstract:Nucleic acid nanostructures offer unique opportunities for biomedical applications due to their sequence-programmable structures and functions, which enable the design of complex responses to molecular cues. Control of the biological activity of therapeutic cargoes based on endogenous molecular signatures holds the potential to overcome major hurdles in translational research: cell specificity and off-target effects. Endogenous microRNAs can be used to profile cell type and cell state and are ideal inputs for RNA nanodevices. Here we present CRISPR MiRAGE (miRNA-activated genome editing), a tool comprising a dynamic single-guide RNA that senses miRNA complexed with Argonaute proteins and controls downstream CRISPR activity based on the detected miRNA signature. We study the operation of the miRNA-sensing single-guide RNA and attain muscle-specific activation of gene editing through CRISPR MiRAGE in models of Duchenne muscular dystrophy. By enabling RNA-controlled gene editing activity, this technology creates opportunities to advance tissue-specific CRISPR treatments for human diseases.

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to improve the spatial and temporal precision of CRISPR gene - editing technology, especially in terms of tissue specificity. Specifically, the researchers have developed a technology named CRISPR MiRAGE (miRNA - activated genome editing). By designing single - guide RNAs (sgRNAs) that can respond to specific microRNAs (miRNAs), precise control of CRISPR - Cas9 activity is achieved. This method aims to reduce off - target effects and genotoxicity, which are the main obstacles faced by CRISPR technology in clinical applications. ### Main research objectives: 1. **Improve the tissue specificity of CRISPR gene editing**: By utilizing the specific miRNA expression profiles within cells, CRISPR MiRAGE can activate gene editing in specific tissues or cell types, thus avoiding editing activities in non - target tissues. 2. **Reduce off - target effects**: By designing sgRNAs that can respond to specific miRNAs, it is ensured that CRISPR - Cas9 will only be activated in the presence of specific miRNAs, thereby reducing the off - target risk. 3. **Verify the effectiveness of the technology**: Verify the feasibility and effectiveness of the CRISPR MiRAGE technology in in - vitro and in - vivo models of Duchenne muscular dystrophy (DMD). ### Key technical features: - **miRNA - sensing sgRNA**: A sgRNA containing a self - complementary "trigger" hairpin structure has been designed. This structure can be recognized and dissociated by specific miRNAs, thereby activating the editing function of CRISPR - Cas9. - **Optimize the stability of the trigger hairpin**: By introducing mismatched bases to regulate the stability of the hairpin, it is ensured that the sgRNA remains inactive in the absence of specific miRNAs. - **Multi - miRNA response system**: A multi - sensing system capable of responding to multiple miRNAs simultaneously has been developed to improve the accuracy of tissue specificity. ### Experimental verification: - **Fluorescence reporting system**: The ability of miRNA - specific activation of gene editing has been verified using a fluorescence reporting system. - **DMD model**: The effect of the CRISPR MiRAGE technology in restoring dystrophin expression has been verified in muscle cells derived from DMD patients and mdx mouse models. ### Conclusion: The CRISPR MiRAGE technology achieves precise control of CRISPR - Cas9 activity by utilizing the miRNA expression profiles within cells, thereby improving the tissue specificity and safety of gene editing. The successful application of this technology in DMD models demonstrates its potential in treating genetic diseases.

Tissue-specific modulation of CRISPR activity by miRNA-sensing guide RNAs

Specific Modulation of CRISPR Transcriptional Activators through RNA-Sensing Guide RNAs in Mammalian Cells and Zebrafish Embryos

Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing

Programmable DNA Repair with CRISPRa/i Enhanced Homology-Directed Repair Efficiency with a Single Cas9

MiRNA-Responsive CRISPR-Cas System via a DNA Regulator

Conditional Control of RNA-guided Nucleic Acid Cleavage and Gene Editing

On RNA-programmable gene modulation as a versatile set of principles targeting muscular dystrophies

Programmable System of Cas13-Mediated RNA Modification and Its Biological and Biomedical Applications

Aptazyme-mediated Direct Modulation of Post-Transcriptional Sgrna Level for Conditional Genome Editing and Gene Expression.

CRISPR innovations in tissue engineering and gene editing

A microRNA-inducible CRISPR–Cas9 platform serves as a microRNA sensor and cell-type-specific genome regulation tool

Modulating CRISPR/Cas9 genome-editing activity by small molecules

In Vivo Target Gene Activation via CRISPR/Cas9-Mediated Trans-epigenetic Modulation

Cell-specific CRISPR/Cas9 activation by microRNA-dependent expression of anti-CRISPR proteins

Spatiotemporal control of CRISPR/Cas9 gene editing

A Conformational Restriction Strategy for the Control of CRISPR/Cas Gene Editing with Photoactivatable Guide RNAs**

A Protocol to Build Microrna-Inducible CRISPR-Cas9 Platform

Expression of Single mRNA Constructs Encoding Both CRISPR-Cas9 Protein and Guide RNAs for Future Gene Therapy Applications

Cell-specific CRISPR–Cas9 activation by microRNA-dependent expression of anti-CRISPR proteins

CRISPR/Cas9 Genome Editing for Tissue‐Specific In Vivo Targeting: Nanomaterials and Translational Perspective

Precision Control of Cell Type‐Specific Behavior via RNA Sensing and Editing